Table 3.
Summary of sensitivity of primary AML cell culture with emvododstat, brequinar, and teriflunomide.
| Compound | Patient Number | ||||
|---|---|---|---|---|---|
| AML293 | AML294 | AML295 | AML299 | AML303 | |
| Emvododstat, CC50 (nM) | 22 | 26 | 31 | 18 | >10,000 |
| Brequinar, CC50 (nM) | 219 | 397 | 23,682 | 251 | >10,000 |
| Teriflunomide, CC50 (nM) | 7,280 | >10,000 | 12,439 | 7,378 | >10,000 |
Each patient sample was treated for 72 hours with DMSO, emvododstat (32 to 10,000 nM), brequinar (32 to 10,000 nM), or teriflunomide (32 to 10,000 nM). The concentration to reduce blast number by 50% (CC50) was calculated by assuming the percent inhibition increased linearly from 0% to 50%.